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Purpose—Cediranib is a multi-tyrosine kinase inhibitor targeting vascular endothelial growth 
factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) 
receptors. This phase II study was conducted to assess activity and tolerability of single-agent 
cediranib in recurrent/persistent endometrial cancer.
Patients and Methods—Eligible patients had recurrent or persistent endometrial cancer after 
receiving one or two prior cytotoxic regimens, measurable disease, and Gynecologic Oncology 
Group (GOG) performance status of ≤2 (≤1 if two prior cytotoxic regimens given). Cediranib 30 
mg orally daily for a 28 day cycle was administered until disease progression or prohibitive 
toxicity. Microvessel density (MVD) was measured in tumor tissue from initial hysterectomy 
specimens and correlated with clinical outcome. Primary endpoints were tumor response and 
surviving progression-free for six months without subsequent therapy (6-month event-free 
survival [EFS]).
Results—Of 53 patients enrolled, 48 were evaluable for cediranib efficacy and toxicity. Median 
age was 65.5 years, 52% of patients had received prior radiation, and 73% of patients received 
only one prior chemotherapy regimen. A partial response was observed in 12.5%. Fourteen 
patients (29%) had six-month EFS. Median progression-free survival (PFS) was 3.65 months and 
median overall survival (OS) 12.5 months. No grade 4 or 5 toxicities were observed. A trend 
towards improved PFS was found in patients whose tumors expressed high MVD.
Conclusion—Cediranib as a monotherapy treatment for recurrent or persistent endometrial 
cancer is well tolerated and met protocol set objectives for sufficient activity to warrant further 
investigation. MVD may be a useful biomarker for activity.
Keywords
targeted therapy; tyrosine kinase inhibitor; angiogenesis; vascular endothelial growth factor 
receptor; platelet derived growth factor receptor; fibroblast growth factor receptor
INTRODUCTION
The estimated number of new uterine corpus cancer cases diagnosed in the United States last 
year increased by 5% to 49,560 [1]. Although most cases of endometrial cancer will be 
cured with surgery alone, approximately 50% with advanced disease will recur [1]. The 
long-term survival for women diagnosed with metastatic, recurrent endometrial cancer is 
poor, with limited responses to current therapy. Deaths from endometrial cancer are on the 
rise, and relative five-year survival has steadily worsened over the past decades, dropping 
from 88% in 1977 to 84% in 2006 to 81.5% in 2014 [2,3].
Primary treatment for advanced or recurrent metastatic endometrial cancer usually includes 
platinum-based therapy in combination with paclitaxel and/or doxorubicin (Gynecologic 
Oncology Group [GOG] 209) [4]. The overall survival (OS) for this population is limited 
(median OS 32–38 months) and has led to efforts to exploit other targets involved in tumor 
cell growth [4]. In particular, the epidermal growth factor receptor (EGFR), vascular 
endothelial growth factor receptor (VEGFR) and mammalian target of rapamycin (mTOR) 
are involved in signaling cascades which act as primary downstream controllers of 
proliferation and apoptosis. For patients with recurrent endometrial cancer who failed 
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chemotherapy, clinical activity was observed by targeting growth factors with bevacizumab 
alone (13.5% clinical response, 40.4% progression-free survival (PFS) for at least six 
months) and bevacizumab with temsirolimus (24.5% clinical response, 46.9% PFS for at 
least six months) [5,6]. The impressive six-month PFS associated with these agents led to a 
trial evaluating these agents in combination with standard cytotoxic chemotherapy, for the 
primary treatment of advanced metastatic or recurrent disease (GOG-86P, ClinicalTrials.gov 
Identifier: NCT00977574). GOG 86P recently completed accrual and is now closed with 
results pending.
Cediranib is an oral agent that inhibits tyrosine kinase activity of all VEGFRs, platelet-
derived growth factor (PDGF) receptors alpha and beta, and fibroblast growth factor (FGF) 
receptor 1. Cediranib monotherapy, studied in phase I trials of solid tumors (colorectal, 
gastrointestinal, breast, skin/soft tissue, prostate, and renal cell) is generally well-tolerated 
[7]. Among patients with glioblastoma, a 45 mg daily dose observed a decrease in tumor 
enhancement in 75% of patients [8]. Patients with epithelial ovarian cancer, primary 
peritoneal cancer, or fallopian tube cancer demonstrated a 30% clinical benefit (defined as 
complete response or partial response, stable disease >16 weeks, or CA-125 nonprogression 
>16 weeks), with cediranib monotherapy [9]. More recently, treatment with cediranib, in 
combination with chemotherapy (platinum/taxane regimen), for platinum-sensitive recurrent 
ovarian cancer and recurrent cervical cancer was found to be well-tolerated with significant 
increases in PFS [10, 11, 12].
GOG 229J was a phase II trial of single-agent cediranib for patients with recurrent or 
persistent endometrial cancer. The primary objective was to evaluate the efficacy of 
cediranib in this population defined by the probability of clinical response and PFS without 
going onto a subsequent therapy for at least six months (six-month event-free survival 
[EFS]).
Patients and Methods
Eligible patients were required to have recurrent or persistent endometrial cancer and who 
met the following criteria: Histologic confirmation of the primary tumor completed by 
central pathology review by the GOG Pathology Committee; measurable disease was 
present, defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); 
GOG performance status of 0–2 if one prior cytotoxic regimen was given or a GOG 
performance status of 0–1 if two prior cytotoxic regimens had been administered; any prior 
therapy directed at the endometrial cancer must be discontinued at least three weeks prior to 
registration; any hormonal therapy directed at the malignant tumor must be discontinued at 
least one week prior to registration; free of active infection requiring antibiotics; adequate 
hematologic parameters (absolute neutrophil count greater than or equal to 1500/mcl, 
platelets ≥100,000/mcl), creatinine ≤1.5 × the institutional upper limit normal or creatinine 
clearance ≥60 ml/min, adequate hepatic function (bilirubin ≤1.5 × upper limit normal, 
SGOT [AST] less ≤2.5 × upper limit normal, alkaline phosphatase ≤2.5 × upper limit 
normal), neuropathy (sensory and motor) ≤ grade 1 (Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.0), urine protein/creatinine ratio <1.0 gm, adequate 
blood coagulation parameters (International Normalized Ratio [INR] is ≤1.5 × upper limit 
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normal, or an in range INR [between 2 and 3] if a patient is on a stable dose of warfarin, and 
a PTT ≤1.5 × upper limit normal), amylase and lipase ≤ upper limit normal, thyroid 
stimulating hormone (TSH) level and a free thyroxine (Free T4) level within institutional 
normal limits; a signed approved informed consent in accordance with federal, state, and 
local requirements; and authorization permitting release of personal health information. The 
protocol was approved by institutional review boards.
Patients were ineligible if they met any of the following criteria: Prior treatment with 
cediranib (AZD 2171) or other VEGF pathway-targeted therapy; prior therapy with any non-
cytotoxic chemotherapy other than hormonal therapy; history of other invasive malignancies 
(except non-melanomatous skin cancer) evident within three years of prior cancer treatment 
that contradicts patient eligibility; prior radiotherapy to any portion of the abdominal cavity 
or pelvis other than for the treatment of endometrial cancer within the last three years; 
presence of serious, non-healing wound, ulcer, or bone fracture, including abdominal fistula, 
gastrointestinal perforation or intra-abdominal abscess within 28 days; active bleeding or 
pathologic conditions that carry high risk of bleeding (bleeding disorder, coagulopathy, 
tumor involving major vessels); Central nervous system (CNS) disease including primary 
brain tumor, uncontrolled seizures or any brain metastases; clinically significant 
cardiovascular disease (uncontrolled hypertension [systolic >150 mmHg, diastolic >100 
mmHg]), myocardial infarction or unstable angina within past six months, New York Heart 
Association Grade II or greater congestive heart failure or serious cardiac arrhythmia 
requiring medication; prior anthracycline treatment (doxorubicin or liposomal doxorubicin) 
with an ejection fraction less than institutional lower limit normal; CTCAE grade 2 or 
greater peripheral vascular disease; history of cerebrovascular accident (CVA), stroke, 
transient ischemic attack (TIA), or subarachnoid hemorrhage within six months of initiating 
cediranib therapy; familial history of long QT syndrome or mean QTc > 500 msec; major 
surgical procedure within 28 days of the initiation of the study.
Treatment
Enrolled patients were to receive cediranib (AZD2171) orally at a dose of 30 mg per day for 
28 days (one cycle) with a dose modification based on toxicity assessed by history, physical 
examination, and laboratory assessment before each treatment cycle with adverse events 
defined and graded according to CTCAE, version 4.0. A single dose reduction to 20 mg per 
day for subsequent treatment was allowed. Cediranib was held for peripheral neuropathy ≥ 
grade 2, renal toxicity ≥ grade 2, or other grade 3 or greater non hematologic toxicities for a 
maximum of two weeks to allow recovery to ≤ grade 1. If toxicities did not resolve to ≤ 
grade 1 after two weeks of withholding cediranib, therapy on the trial was stopped. 
Cediranib was also discontinued for arterial thrombosis ≥ grade 2; a diagnosis of reversible 
posterior leukoencephalopathy; grade 4 hypertension; grade 3 symptomatic hypertension 
requiring hospitalization; gastrointestinal perforation, leak or fistula; wound separation or 
dehiscence requiring intervention; central nervous system (CNS) or pulmonary hemorrhage 
≥ grade 2; and grade 4 proteinuria. Specific guidelines were implemented for modifying the 
treatment in the event of hypertension, proteinuria, and non-CNS, non-pulmonary 
hemorrhage. There were no dose escalations or re-escalations during the study.
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Evaluation Criteria
Activity of cediranib was assessed according to RECIST 1.1. Measurable and non-
measurable disease was assessed by radiographic imaging at baseline, before every other 
cycle for the first six months using the same technique as that which was used at baseline, 
and then every three months thereafter until disease progression was confirmed.
Microvessel Density Evaluation by Immunohistochemistry
Tissue was submitted from the primary hysterectomy for microvessel density (MVD) 
immunostaining. After tissue deparafinization and hydration, epitope retrieval in a pressure 
cooker with 10 mmol/L citrate buffer with pH 6.0 was initiated. Peroxidase quenching was 
done by incubation at 3% Hydrogen peroxide for 8 minutes. The primary antibody used was 
monoclonal mouse anti-human CD31 (platelet/endothelial cell adhesion molecule-1, product 
# M0823, Dako) 1:20 dilution for 15 minutes. The slides were then incubated in mouse 
DAKO EnVision ™ HRP System for 15 minutes followed by DAB chromagen for 5 
minutes and DAB enhancer for 3 minutes. The specimens were counterstained in 
hematoxylin for 1 minute and mounted. Normal colonic epithelium was used as a positive 
control as suggested by the manufacturer, while colonic tissue devoid of primary antibody 
was used as a negative control [13]. The slides were sequentially reviewed by two blinded 
investigators. Each slide was manually scanned under low magnification (100×) to identify 
and select three different regions or “hot-spots” with the highest vascularity. The blood 
vessel density in a 0.75 mm2 area per hotspot was counted under 200× magnification. MVD 
staining was counted within the tumor and tumor margins. Any endothelial cell or group of 
cells that stained positive for CD31 and was distinct from neighboring fibroblasts or tumor 
cells was counted as a microvessel. The average of the values obtained by the two reviewers 
for each hot-spot was reported as a single numerical value, and the mean count from the 
three regions was used to determine the MVD score. A score of ≤25 vessels /high power 
field (HPF) was considered as low and a score of >25 vessels/HPF as high [14]. Final results 
were then confirmed by a pathologist designated as the GOG liaison for the University of 
Iowa, but not an investigator on the trial.
Statistics
The primary objective was to evaluate the efficacy of cediranib through the frequency of 
patients who either had objective tumor responses or who achieved six-month event-free 
survival (EFS). Activity on either dimension is indicative of a regimen worthy of further 
investigation. The null hypothesis, derived from historical data [5], specified uninteresting 
probabilities of response and six-month EFS equal to 10% and 15%, respectively. The 
probability of six-month EFS was approximated with historical data using six-month PFS. 
EFS is defined as the time from study entry to progression of disease, initiation of another 
therapy, or death. EFS was chosen as the primary endpoint since it was expected to reduce 
the rate of incorrectly declaring cediranib an “active” agent. Clinically significant 
improvements of probabilities under the alternative hypothesis were 25% and 35% for 
response and six-month EFS. The study accrued patients in two stages using the method of 
Sill et al [15]. With 27 patients accrued to the first stage, the critical values were 3 and 4 for 
the number who responded or were six-month EFS. With 48 patients accrued cumulatively, 
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the critical values were 7 and 12 for response and six-month EFS. The study was flexible 
with actual accrual and had approximately 90% power at the 10% level of significance. The 
probability of early termination was likely between 46 and 57% under the null, dependent of 
the true association between response and six-month EFS.
Additonal endpoints of the study included adverse events attributed to the investigational 
agent as well as the duration of PFS, EFS, and OS. Time at risk was assessed from the date 
of enrollment. Per the protocol, patients retrospectively not meeting eligibility criteria or 
who received no investigational therapy were excluded from all analyses. Translational 
research was carried out in an exploratory fashion to generate hypotheses for future studies. 
The proposed hypothesis for the translational work was that response to the multi-tyrosine 
kinase activity of cediranib is related to higher microvessel density, reflective of greater 
tumor vascularity, in pretreatment specimens. Associations were examined using 
Spearman’s correlation and Cox regression [16,17]. Associations detected with p-values 
<0.05 were deemed “suggestive.” Associations with 0.05 < p-values <0.10 were deemed as 
a “trend.”
RESULTS
From June 2010 to April 2012 GOG member institutions enrolled 53 patients onto this trial. 
Five patients were deemed ineligible or inevaluable because of wrong primary cancer cell 
type (n=1), inadequate pathology for central review (n=1), never administered 
investigational agent (n=1), inadequate data for central review (n=1), and prior treatment 
making them ineligible (n=1). The remaining 48 patients were assessed for toxicity and 
efficacy. Patient characteristics are presented in Table 1. Approximately 73% of patients 
received only one prior chemotherapy regimen and 52% received prior radiation therapy. 
Patient outcomes are presented in Table 2. Thirty patients have died from disease. A median 
of two cycles of cediranib were administered (range, 1–15). Forty-eight percent received at 
least three cycles of study therapy and 31.3% received six or more cycles. Among patients 
who discontinued therapy, 64.6% stopped for disease progression and 29.2% stopped for 
toxicity as directed by the protocol.
Adverse Events
The safety of cediranib in all 48 patients was analyzed descriptively (Table 3). No fatal 
events occurred as a result of the study drug and no grade 4 or 5 toxicities were attributed to 
the investigational agent. Vascular disorders accounted for the most common grade 3 
toxicity which included hypertension (n=16) and pulmonary embolus (n=3). Two of the 
patients with hypertension experienced non-life-threatening hemorrhage, leading to 
cessation of the study. Seven patients experienced grade 3 diarrhea and 10 patients reported 
grade 3 fatigue. During study treatment, one patient sustained a colonic perforation; another 
developed ischemic bowel in the presence of a hernia, and a third developed a rectal fistula 
where tumor progression in the rectovaginal septum was noted. Cediranib was possibly 
related to the colonic perforation, but deemed unrelated and unlikely related to the rectal 
fistula and the ischemic bowel, respectively. Among the three patients with significant 
bowel complications, radiation (vaginal brachytherapy) had been previously administered 
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only to the individual who sustained a colonic perforation. Reversible posterior 
leukoencephalopathy was diagnosed in a single patient.
Activity of Cediranib
The activity of cediranib was analyzed in 48 patients (Table 2). Six patients had a partial 
response for an overall response rate (ORR) of 12.5% (90% 2-sided CI for the probability of 
response 5.6% – 26.8%). The drug was not sufficiently active by its ORR to declare it 
interesting. Stable disease was observed in 18 (37.5%) patients. Fourteen patients had six-
month EFS (29.2%; 90% 2-sided confidence interval (CI) is 18.6 ~ 41.9%). Sixteen patients 
(33.3%, 90% two-sided CI 22 ~ 46%) had six-month PFS. The frequency of patients who 
had six-month EFS met criteria for declaring this regimen active. The median EFS was 3.61 
months. The median PFS was 3.65 months, and the median OS was 12.5 months (Figure 1).
Microvessel Density (MVD) as a predictor of progression-free survival
Among the 48 evaluable patients in this trial, histologic slides were available for 42 
pretreatment hysterectomy specimens. Three cases had insufficient tissue on the slides to 
complete the MVD assays. Forty-two cases had formalin-fixed, paraffin-embedded (FFPE) 
tissue submitted from the primary hysterectomy for MVD immunostaining. Data were 
obtained on 39 patients with primary tumor tissue. Of the 39 evaluable cases stained for 
MVD, 17 had high MVD and 22 had low MVD (Figure 2). Median PFS in cases with high 
MVD was 4.3 months vs. 3.5 months for patients with low MVD (Figure 3). The estimated 
hazard ratio was 0.51 (95% 2-sided CI 0.25 ~ 1.04). This indicated a trend towards 
prolonged PFS in patients with high MVD.
DISCUSSION
Endometrial cancer is the most common gynecologic malignancy in the US, and the 
prognosis is poor for patients with advanced disease. This trial, GOG 229J, tested the 
hypothesis that the oral multi-tyrosine kinase inhibitor cediranib (AZD 2171) is a tolerable 
oral therapy and would demonstrate a clinically significant six-month event-free survival in 
patients with recurrent or advanced disease who had previously failed chemotherapy. The 
results of this trial identify cediranib as among one of the first tyrosine kinase inhibitors, 
studied by the GOG, with sufficient activity to warrant further investigation in advanced 
endometrial cancer.
Several phase II trials have examined the efficacy of targeted molecular inhibitors in patients 
with advanced or recurrent endometrial cancer [5,6,18–20]. Bevacizumab (anti-VEGF 
antibody) and temsirolimus (anti-mTOR small molecule) were the first targeted agents to 
demonstrate clinical activity [5,21]. Cediranib (AZD 2171) is an oral agent that inhibits 
tyrosine kinase activity in all VEGF receptors and PDGF receptors alpha and beta. Anti-
tumor activity has been demonstrated both in tumor xenograft models of various types of 
cancer as well as in clinical trials of cediranib monotherapy [7,8,22]. Cediranib was well 
tolerated in each monotherapy trial. The tolerability, ease of administration, and clinical 
observations with cediranib therapy made this drug a compelling choice for investigation in 
patients with recurrent or persistent endometrial cancer.
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Tumor xenograft mouse models for colon, lung, prostate, breast, and ovarian cancer have 
demonstrated a response to once daily dosing of cediranib as evidenced by a reduction in 
tumor growth, tumor vessel density, and vascular regression [22]. Similar anti-tumor activity 
was observed in initial clinical trials where a single daily oral dose of cediranib was used in 
patients with advanced solid tumors [11]. Further investigation of cediranib activity in 
ovarian, fallopian tube, and peritoneal cancers identified clinical benefit which ultimately 
led to trials using this agent in combination with cytotoxic chemotherapy for platinum-
sensitive ovarian cancer. The International Collaboration for Ovarian Neoplasia 6 (ICON 6) 
trial showed cediranib to be sufficiently well tolerated on initial toxicity assessment such 
that it progressed to stage 2 [10]. Four-hundred-fifty-six patients were recruited into this trial 
and initial reports indicated that the trial met its primary endpoint. Patients receiving 
cediranib with chemotherapy plus maintenance cediranib had significantly improved PFS 
(medians 9.4 to 12.5 months; HR 0.57; log rank test p=0.00001) compared to those who 
received chemotherapy alone [11]. Efficacy was also observed in the Cediranib In Recurrent 
Cervical Cancer (CIRCCa) phase II trial of carboplatin and paclitaxel in combination with 
cediranib or placebo in patients with relapsed or metastatic cervical cancer [12]. 
Specifically, response rates were 66% for the 34 patients who received cediranib vs. 42% for 
the 35 patients who received placebo, with a modest but significant increase in PFS from 30 
to 35 weeks. Clinical benefit has also been observed for cediranib combined with 
chemotherapy in the treatment of chemotherapy-naïve patients with advanced non-small cell 
lung cancer; 40% demonstrated a partial response to cediranib in combination with 
carboplatin and paclitaxel, while 53% of the 15 patients had stable disease [23].
Data from this trial, GOG-229J, are comparable to the findings of GOG-229E, where 
bevacizumab treatment resulted in a response rate of 13.5%, and 40% of patients had PFS 
greater than six months. While no direct comparison of efficacy has been studied between 
cediranib and bevacizumab, the multi-targeted anti-angiogenic TKI was felt to potentially 
have greater theoretical benefit due to the additional blockade of PDGF and FGF receptors. 
PDGF receptors are highly expressed in uterine cancers and multiple FGF receptors and 
their ligands have been identified in endometrial cells and their respective tumors [24, 25]. 
Cediranib, like bevacizumab, demonstrated a clinically significant 6-month PFS (33.3%) 
and should also be considered an agent of clinical interest in this disease. Although cediranib 
was well tolerated with no grade 4 or 5 toxicities, 14 (29.2%) patients discontinued therapy 
due to toxicity as permitted by the protocol. The rate of discontinuing therapy for toxicity-
related reasons for this tyrosine kinase inhibitor is considerably higher than the 5.8% rate 
which was reported for the pure VEGF antagonist, bevacizumab, in GOG-229E. Perhaps the 
additional blocking activity of FGF and PDGF receptors led to higher rates of grade 3 
diarrhea (15%) and grade 3 fatigue (21%), neither of which were reported at grade 3 levels 
with bevacizumab. In short, patients who are treated with cediranib should be carefully 
followed for not only the toxicities commonly reported among agents blocking VEGF 
activity, but also for diarrhea and fatigue as seen in this trial.
In order to refine the patient population most likely to respond to cediranib, we performed 
MVD analyses of patient tumors using FFPE slides from the original hysterectomy blocks. 
We reasoned that cediranib, as an inhibitor of angiogenesis, may be particularly effective 
against tumors with high MVD. Our clinical data show a prognostic relationship between 
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MVD and PFS and may be among the first to confirm pre-clinical observations that tumors 
with high MVD respond best to anti-angiogenic therapy [26]. Our finding is particularly 
interesting, first, because the studies were performed on the original tumor, not on the 
recurrent lesions. Hence, these data speculate that high MVD may be a consistent tumor 
characteristic which is predictable at the outset of therapy. Second, it is expected that tumors 
with high MVD may be the most aggressive lesions in the absence of anti-angiogenic 
treatment and would otherwise portend a poor prognosis. The fact that high MVD may be 
associated with longer PFS in patients on anti-angiogenic treatment such as cediranib 
underscores the potential benefit of these agents. The limitations of our study include the 
relatively small sample size, a lack of concurrent control, insufficient tissue or histology 
slides available for nine pretreatment tumor specimens, and the fact that these are recurrent 
cases. The missing data were assumed to be missing completely at random, a hypothesis 
difficult to verify. In fact, with 20% of the population missing, the analysis could be biased 
to a considerable degree, so caution should be exercised when interpreting it. The original 
tumor phenotype at hysterectomy (the source for the MVD analysis in this study) may not 
fully represent the phenotype of the recurrent cancer. Also, the absence of a control group in 
this study prevents the determination of MVD as a predictive biomarker, and should be 
addressed in future clinical trials where chemotherapy is used with and without cediranib. 
Nevertheless, these data, when considered in aggregate with the reports from others [27, 28], 
indicate that MVD may be a useful discriminator of tumors most likely to respond to anti-
angiogenic agents.
In conclusion, the tyrosine kinase inhibitor, cediranib, was shown in GOG-229J to have 
sufficient activity against endometrial cancer, warranting further treatment strategies with 
this agent. Multiple studies have supported its use as a single agent as well as in combination 
with cytotoxic chemotherapy for a variety of gynecologic and non-gynecologic 
malignancies. Therefore, given the need to address the evidence of increasing incidence and 
decreasing survival in women with advanced endometrial cancer, we propose similar 
combinations of cediranib with cytotoxic agents be considered for this population.
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RESEARCH HIGHLIGHTS
• Cediranib is an active multi-tyrosine kinase inhibitor in uterine cancer
• Cediranib for recurrent uterine cancer had a 33% six-month progression free 
survival
• Cediranib is a safe and well-tolerated oral treatment for recurrent uterine cancer
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Figure 1. Progression-free survival (PFS) and overall survival (OS) of endometrial cancer 
patients receiving single agent cediranib
Kaplan-Meier plot of progression-free survival (solid line) and overall survival (dashed 
line). The median PFS was 3.65 (90% CI 2.37 ~ 5.49). The median OS was 12.5 (90% CI 
7.0 ~ 14.5).
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Figure 2. Microvessel density (MVD) as determined by immunostaining for cluster of 
differentiation 31 (CD31)
Top image (A) is a photomicrograph of endometrial cancer with strong staining for CD31 
and MVD score = 81.3. Bottom image (B) is a photomicrograph of a tumor with low 
staining for CD31 and MVD score = 8.3.
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Figure 3. Progression-free survival (PFS) as a function of microvessel density
A trend towards improved PFS in patients with high MVD (solid line) is suggested.
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Table 1
Patient characteristics
Characteristic Category No. %
Age 40–49 3 6.3
50–59 10 20.8
60–69 20 41.7
70–79 12 25.0
80–89 3 6.3
Race African-American 2 4.2
White 46 95.8
Performance Status 0 36 75.0
1 10 20.8
2 2 4.2
Cell Type/Grade Endometrioid, grade 1 3 6.3
Endometrioid, grade 2 14 29.2
Endometrioid, grade 3 7 14.6
Serous 11 22.9
Clear Cell 3 6.3
Mixed Epithelial 10 20.8
Prior Chemotherapy 1 Prior Regimen 35 72.9
2 Prior Regimens 13 27.1
Prior Radiation No 23 47.9
Yes 25 52.1
Prior Immunotherapy No 48 100.0
Prior Surgery No 1 2.1
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Table 2
Patient outcomes
Characteristics Category No. %
Response Partial response 6 12.5
Stable disease 18 37.5
Increase disease 17 35.4
Indeterminate 7 14.6
PFS > 6 Months No 32 66.7
Yes 16 33.3
EFS > 6 Months No 34 70.8
Yes 14 29.2
Cycles of Treatment 1 10 20.8
2 15 31.3
3 1 2.1
4 6 12.5
5 1 2.1
6 7 14.6
8+ 8 16.7
Off Study Yes 48 100.0
Why Off Study Disease progression 31 64.6
Refused further treatment 1 2.1
Toxicity as permitted 14 29.2
Death 1 2.1
Other 1 2.1
Alive Without progression 2 4.2
With progression 16 33.3
Dead From disease 28 58.3
From Rx & disease 2 4.2
The 90% confidence interval (CI) for the probability of response is 5.6% ~ 26.8%. The 90% 2-sided CI for event-free survival (EFS) >6 months is 
18.6% ~ 41.9%. The 90% 1-sided CI for EFS >6 months is 20.5% ~ 100%.
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